Overview Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003) Status: Completed Trial end date: 2007-09-24 Target enrollment: Participant gender: Summary This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.Vyne Therapeutics Inc.